EDITAS MEDICINE, INC. Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2022-06-30 was $367.00K, a 30.23% decline year-over-year.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2021-06-30 was $526.00K, a 50.29% increase year-over-year.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2020-06-30 was $350.00K, a 23.67% increase year-over-year.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2019-06-30 was $283.00K, a 21.82% decline year-over-year.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2024 was $590.00K, a 35.80% decline from fiscal 2023.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $919.00K, a 6.13% decline from fiscal 2022.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2022 was $979.00K, a 15.02% decline from fiscal 2021.
- EDITAS MEDICINE, INC. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2021 was $1.15M, a 28.57% increase from fiscal 2020.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|
| 2024-12-31 | $590.00K 10-K · filed 2025-03-05 | |
| 2023-12-31 | $919.00K 10-K · filed 2025-03-05 | |
| 2022-12-31 | $979.00K 10-K · filed 2025-03-05 | |
| 2022-06-30 | $367.00K 10-Q · filed 2022-11-02 | |
| 2021-12-31 | $1.15M 10-K · filed 2024-02-28 | |
| 2021-06-30 | $526.00K 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $896.00K 10-K · filed 2023-02-22 | |
| 2020-06-30 | $350.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $620.00K 10-K · filed 2022-02-24 | |
| 2019-06-30 | $283.00K 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $680.00K 10-K · filed 2021-02-26 | |
| 2018-06-30 | $362.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |